Current Rabies Post-Exposure Prophylaxis Recommendations

Introduction to Rabies PEP

• The Advisory Committee on Immunization Practices (ACIP) recommends a 4-dose vaccine schedule for previously unvaccinated individuals, with doses given on days 0, 3, 7, and 14, as part of the current rabies post-exposure prophylaxis regimen 1, 2, 3

Components of Rabies PEP

• Immediate thorough cleansing of all wounds with soap and water for 15 minutes, followed by irrigation with a virucidal agent, is essential for reducing the likelihood of rabies infection 2, 4
• Human rabies immune globulin (HRIG) should be administered at 20 IU/kg body weight for previously unvaccinated individuals 2
• The full dose of HRIG should be infiltrated around and into the wound(s) if anatomically feasible, with any remaining volume administered intramuscularly at a site distant from vaccine administration 2, 3, 5
• HRIG should not be administered in the same syringe as the vaccine, and it can be given up to and including day 7 of the PEP series 2

Vaccination Schedule

• The vaccine regimen consists of human diploid cell vaccine (HDCV) or purified chick embryo cell vaccine (PCECV), 1.0 mL per dose, administered intramuscularly in the deltoid area (or anterolateral thigh in young children) 2, 3
• The 4-dose schedule is given on days 0, 3, 7, and 14, with day 0 being the day the first dose is administered 1, 2, 3
• The gluteal area should never be used for vaccine administration as it may result in diminished immune response 2, 3

Special Considerations

• Immunosuppressed individuals should receive the full 5-dose regimen (days 0, 3, 7, 14, and 28) 2, 3
• Previously vaccinated persons require only 2 doses of vaccine (on days 0 and 3) and do not need HRIG administration 2, 6
• Serologic testing to confirm seroconversion is not necessary in immunocompetent individuals following completion of PEP, but is recommended for immunosuppressed patients if seroconversion fails 6

Timing and Efficacy

• PEP should be initiated as soon as possible after exposure, and when administered promptly and appropriately, is nearly 100% effective in preventing human rabies 1, 4
• The incubation period for rabies is typically 1-3 months but can range from days to over a year 4

Rabies Post-Exposure Prophylaxis Guidelines

Vaccination Schedule

• The Centers for Disease Control and Prevention recommends administering 4 doses of rabies vaccine on days 0, 3, 7, and 14 for category 2 exposures, without rabies immunoglobulin (RIG), for a 4-year-old child 7, 8
• For pediatric patients, including young children, the 4-dose schedule applies, and the vaccine should be injected intramuscularly in the anterolateral thigh 7, 8
• If the child is immunocompromised, a 5-dose regimen (days 0, 3, 7, 14, and 28) with RIG is recommended, even for category 2 exposures 9

Special Considerations

• The World Health Organization defines category 2 exposures as nibbling of uncovered skin or minor scratches/abrasions without bleeding, which do not require RIG administration 7, 8
• The vaccine regimen is highly effective when administered properly, with a strength of evidence supporting the 4-dose schedule for all age groups, including young children 7, 8

Rabies Post-Exposure Prophylaxis Guidelines

Introduction to Rabies Prophylaxis

• The Centers for Disease Control and Prevention recommends that rabies vaccination should be initiated as soon as possible after exposure, ideally within 24 hours, though treatment remains indicated even if weeks or months have elapsed since the exposure 10, 11

Critical Timing Principles

• The Advisory Committee on Immunization Practices states that delays of even a few hours matter because rabies is nearly 100% fatal once clinical symptoms develop, and treatment should begin immediately upon recognition of exposure 11

Vaccination Schedule

• The Centers for Disease Control and Prevention recommends that for previously unvaccinated persons, administer 4 doses of rabies vaccine (HDCV or PCECV) intramuscularly on days 0, 3, 7, and 14 12, 11
• Day 0 is defined as the day the first dose is given, not necessarily the day of exposure, as stated by the Centers for Disease Control and Prevention 13, 11
• The vaccine should be administered in the deltoid muscle for adults and older children, or anterolateral thigh for young children—never use the gluteal area as this produces inadequate antibody response, according to the Centers for Disease Control and Prevention 13, 11

Special Populations

• The Centers for Disease Control and Prevention recommends that immunocompromised patients require the older 5-dose regimen (days 0, 3, 7, 14, 28) with HRIG 11
• Previously vaccinated persons need only 2 doses (days 0 and 3) and do not require HRIG, as stated by the Centers for Disease Control and Prevention 11, 14

HRIG Administration

• The Centers for Disease Control and Prevention states that HRIG can be administered up to and including day 7 after the first vaccine dose if it was not given initially 14
• HRIG should not be administered in the same syringe or anatomical site as the vaccine, and the dose should not exceed 20 IU/kg to avoid suppressing active antibody production, according to the Centers for Disease Control and Prevention 14

Wound Care

• The Centers for Disease Control and Prevention recommends that immediate thorough washing of all wounds with soap and water for 15 minutes is perhaps the most effective single measure for preventing rabies 10

Rabies Post-Exposure Prophylaxis Guidelines

Immediate Treatment and Vaccination

• The Centers for Disease Control and Prevention recommends that rabies vaccination should be initiated as soon as possible after exposure, with no absolute cutoff beyond which post-exposure prophylaxis should be withheld, as delays of even hours matter significantly given the uniformly fatal outcome once the virus reaches the central nervous system 15, 16
• The key principle is that once an exposure is recognized, prophylaxis should begin immediately regardless of the time elapsed, with treatment decisions made and successfully implemented many months after exposure when recognition of the exposure was delayed 15, 16

Vaccination Schedule and Administration

• For previously unvaccinated persons, the regimen consists of 4 doses of rabies vaccine administered intramuscularly on days 0, 3, 7, and 14, and human rabies immune globulin (HRIG) at 20 IU/kg body weight, administered on day 0, with HRIG able to be administered up to and including day 7 after the first vaccine dose if it was not given initially 17, 18
• The vaccine administration sites are the deltoid muscle for adults and older children, and the anterolateral thigh for young children, with the gluteal area never used as it produces inadequate antibody response 17, 18, 16

Wound Care and Management

• Immediate thorough washing of all wounds with soap and water for 15 minutes is perhaps the most effective single measure for preventing rabies and should be performed before any other intervention, with local wound treatment shown in animal studies to markedly reduce the likelihood of rabies infection 15, 16

Managing Schedule Deviations

• Delays of a few days for individual doses are unimportant, though the effect of longer lapses of weeks or more is unknown, with most interruptions not requiring restarting the entire series, and for substantial deviations, immune status should be assessed by serologic testing 7-14 days after the final dose 17, 18

Rabies Post-Exposure Prophylaxis Guidelines

Vaccine Administration

• The Centers for Disease Control and Prevention recommends administering 4 doses of HDCV (human diploid cell vaccine) or PCECV (purified chick embryo cell vaccine), 1.0 mL intramuscularly on days 0, 3, 7, and 14, for previously unvaccinated individuals 19
• The vaccine should be injected in the deltoid muscle for adults and older children, and in the anterolateral thigh for young children 19
• The vaccine should never be administered in the gluteal area, as this produces inadequate antibody response 19

Rabies Immune Globulin Administration

• The Centers for Disease Control and Prevention recommends administering HRIG at 20 IU/kg body weight on day 0, ideally at the same time as the first vaccine dose, and infiltrating the full dose around and into the wound(s) if anatomically feasible 19
• HRIG should not be administered in the same syringe or at the same anatomical site as the vaccine 19

Special Populations

• The Centers for Disease Control and Prevention recommends that previously vaccinated individuals require only 2 doses of vaccine (on days 0 and 3) and do NOT need HRIG 19
• Immunocompromised individuals must receive the full 5-dose vaccine regimen (days 0, 3, 7, 14, and 28) plus HRIG at 20 IU/kg, even if previously vaccinated 19
• Children receive the same vaccine dose volume (1.0 mL) as adults, and the anterolateral thigh should be used for vaccine administration in young children 19

Common Pitfalls to Avoid

• The Centers for Disease Control and Prevention advises against using the gluteal area for vaccine administration, as this is associated with vaccine failure due to inadequate immune response 19
• HRIG should not be given to previously vaccinated persons, as it will inhibit the anamnestic response 19
• Immunocompromised patients should be upgraded to the 5-dose regimen, as the standard 4-dose schedule is inadequate for this population 19

Rabies Vaccine Schedule and Dose for Immunocompromised Patients

Post-Exposure Prophylaxis Regimen for Immunocompromised Patients

• Immunocompromised patients require a 5-dose rabies vaccine regimen (days 0, 3, 7, 14, and 28) plus rabies immune globulin (RIG) at 20 IU/kg on day 0, even if they were previously vaccinated, because immunosuppression substantially reduces vaccine response and standard schedules are inadequate 20, 21
• Administer 5 intramuscular doses of 1.0 mL each on days 0, 3, 7, 14, and 28 (not the standard 4-dose schedule used for immunocompetent patients) 20, 21, 22, 23, 24

Critical Considerations for Immunosuppressed Patients

• Corticosteroids, other immunosuppressive agents, antimalarials, and immunosuppressive illnesses (including HIV, chronic lymphoproliferative leukemia) substantially reduce immune responses to rabies vaccines 20, 21, 22, 23, 25
• Even with the 5-dose regimen, the immune response may still be inadequate 20, 21, 22, 23

Mandatory Serologic Testing

• One or more serum samples must be tested for rabies virus-neutralizing antibody by the rapid fluorescent focus inhibition test (RFFIT) after completing the series 20, 21, 22, 23, 25, 26
• Testing should occur 1-2 weeks after the final vaccine dose (day 42 for immunocompromised patients) 26
• An acceptable antibody response is defined as complete neutralization of challenge virus at a 1:5 serum dilution 25, 26
• If no acceptable antibody response is detected, manage the patient in consultation with their physician and public health officials 20, 21, 22

Management of Immunosuppressive Medications

• Immunosuppressive agents should not be administered during rabies PEP unless essential for treatment of other conditions 20, 21, 22, 23

Pre-Exposure Prophylaxis in Immunocompromised Patients

• If possible, postpone rabies pre-exposure prophylaxis until the immunocompromising condition is resolved 20, 21, 22
• Immunocompromised persons at risk for rabies must have their virus-neutralizing antibody responses checked after completing the pre-exposure series 20, 21, 22

Rabies Post-Exposure Prophylaxis Protocol

Immediate Wound Management

• The Centers for Disease Control and Prevention recommends that all bite wounds and scratches must be immediately and thoroughly washed with soap and water for 15 minutes, as this is perhaps the single most effective measure for preventing rabies infection 27
• Local wound treatment with a virucidal agent, if available, has been shown in animal studies to markedly reduce the likelihood of rabies infection 27

Post-Exposure Prophylaxis for Previously Unvaccinated Persons

• The Centers for Disease Control and Prevention recommends that individuals who have never received rabies vaccination should be administered both human rabies immune globulin (HRIG) and a 4-dose vaccine series on days 0, 3, 7, and 14 27
• The vaccine dose should be 1.0 mL per dose, administered intramuscularly, with the schedule being days 0, 3, 7, and 14 (day 0 is the day the first dose is given, not necessarily the day of exposure) 27
• The vaccine should be injected in the deltoid muscle for adults and older children, and in the anterolateral thigh for young children 27

Post-Exposure Prophylaxis for Previously Vaccinated Persons

• The Centers for Disease Control and Prevention recommends that previously vaccinated individuals require only 2 doses of vaccine (on days 0 and 3) and do NOT need HRIG 27, 28
• This applies to persons who have completed a recommended preexposure or postexposure vaccination regimen with a cell culture vaccine 27, 28

Exposure Risk Assessment

• The Centers for Disease Control and Prevention states that rabies transmission requires virus introduction into bite wounds, open cuts in skin, or onto mucous membranes 28
• Any penetration of skin by teeth constitutes a bite exposure requiring evaluation 28
• Nonbite exposures, such as scratches, abrasions, open wounds, or mucous membranes contaminated with saliva or neural tissue from a rabid animal, also constitute exposure 28
• If the material containing virus is dry, the virus is considered noninfectious 28

Rabies Post-Exposure Prophylaxis Schedule

Immediate Wound Management and Vaccine Administration

• The Centers for Disease Control and Prevention recommends washing all wounds thoroughly with soap and water, followed by irrigation using a virucidal agent such as povidone-iodine solution if available, as the first step in preventing rabies infection 29

Standard PEP for Previously Unvaccinated Persons

• The Centers for Disease Control and Prevention recommends administering 4 doses of HDCV or PCECV, 1.0 mL intramuscularly on days 0, 3, 7, and 14, combined with human rabies immune globulin (HRIG) at 20 IU/kg on day 0, for previously unvaccinated persons 29
• The vaccine should be injected in the deltoid muscle for adults and older children, and in the anterolateral thigh for young children, as recommended by the Centers for Disease Control and Prevention 29
• The Centers for Disease Control and Prevention advises against using the gluteal area for vaccine administration, as it produces inadequate antibody response and is associated with vaccine failure 29

HRIG Administration

• The Centers for Disease Control and Prevention recommends administering HRIG at exactly 20 IU/kg body weight on day 0, ideally at the same time as the first vaccine dose, and infiltrating the full dose around and into the wound(s) if anatomically feasible 29
• The Centers for Disease Control and Prevention advises against administering HRIG in the same syringe or at the same anatomical site as the vaccine, and against exceeding 20 IU/kg, as higher doses suppress active antibody production 29

Special Considerations

• The Centers for Disease Control and Prevention recommends administering a 5-dose vaccine regimen on days 0, 3, 7, 14, and 28, plus HRIG at 20 IU/kg on day 0, for immunocompromised patients, even if previously vaccinated 29
• The Centers for Disease Control and Prevention recommends that children receive the same vaccine dose volume (1.0 mL) and HRIG dose (20 IU/kg) as adults 29

Rabies Post-Exposure Prophylaxis Guidelines

Standard PEP Regimen for Previously Unvaccinated Persons

• The Centers for Disease Control and Prevention (CDC) recommends administering 4 doses of rabies vaccine intramuscularly on days 0, 3, 7, and 14, combined with rabies immune globulin (RIG) at 20 IU/kg on day 0, for previously unvaccinated individuals 30
• The vaccine schedule consists of 4 intramuscular doses of 1.0 mL each on days 0, 3, 7, and 14, with day 0 being the day the first dose is given, not necessarily the exposure date 30
• RIG should be administered at 20 IU/kg body weight given once on day 0, ideally simultaneously with the first vaccine dose 30
• The full calculated dose of RIG should be thoroughly infiltrated around and into the wound(s) if anatomically feasible, with any remaining volume injected intramuscularly at a site distant from vaccine administration 30

Critical Administration Details

• The CDC recommends administering vaccine in the deltoid muscle for adults and older children 30
• For young children, the vaccine should be administered in the anterolateral thigh 30
• The gluteal area should never be used for vaccine administration, as it produces inadequate antibody response and has been associated with vaccine failures 30
• RIG should not be administered in the same syringe or at the same anatomical site as the vaccine 30
• The dose of RIG should not exceed 20 IU/kg, as higher amounts suppress active antibody production 30

Immediate Wound Management

• The CDC recommends thoroughly washing all wounds with soap and water for 15 minutes before administering any biologicals, as this single intervention markedly reduces rabies risk in animal studies 31, 30

Modified Regimens for Special Populations

• Previously vaccinated persons require only 2 doses of vaccine on days 0 and 3, and do not receive RIG, as it will inhibit the anamnestic antibody response 30

Timing Considerations

• The CDC recommends initiating PEP as soon as possible after exposure, ideally within 24 hours, but treatment can be started immediately upon recognition of exposure even if weeks or months have elapsed 31
• There is no absolute cutoff for initiating PEP, as rabies incubation periods can exceed one year and the disease is uniformly fatal once symptoms appear 31

Common Clinical Pitfalls

• The CDC advises against withholding treatment while waiting for animal observation results if the exposure occurred in a rabies-endemic area, and treatment can be discontinued if the animal remains healthy after 10 days 31
• The CDC recommends against delaying treatment for serologic testing in previously unvaccinated persons, as routine post-vaccination antibody testing is unnecessary in immunocompetent individuals 30
• The CDC advises against giving RIG to previously vaccinated persons, as this is a critical error that suppresses the memory immune response 30

Rabies Vaccination Schedule

Post-Exposure Prophylaxis for Previously Unvaccinated Persons

• The Centers for Disease Control and Prevention recommends administering a 4-dose vaccine series on days 0, 3, 7, and 14, combined with human rabies immune globulin (HRIG) at 20 IU/kg on day 0 for individuals never vaccinated against rabies who are exposed 32, 33
• The World Health Organization suggests following wound washing with irrigation using a virucidal agent such as povidone-iodine solution if available 32, 33
• Administer 1.0 mL of HDCV (human diploid cell vaccine) or PCECV (purified chick embryo cell vaccine) intramuscularly on days 0, 3, 7, and 14 32, 33
• Inject in the deltoid muscle for adults and older children 32, 33
• Use the anterolateral thigh for young children 32, 33
• Administer HRIG at exactly 20 IU/kg body weight on day 0, ideally simultaneously with the first vaccine dose 32, 33
• Infiltrate the full calculated dose around and into the wound(s) if anatomically feasible 32, 33
• Inject any remaining volume intramuscularly at a site distant from vaccine administration 32, 33

Post-Exposure Prophylaxis for Previously Vaccinated Persons

• The Centers for Disease Control and Prevention recommends that previously vaccinated individuals require only 2 doses of vaccine on days 0 and 3, and do NOT need HRIG 32, 33, 34
• This simplified regimen applies to anyone who has completed a recommended pre-exposure or post-exposure vaccination series with a cell culture vaccine 32, 33, 34

Pre-Exposure Prophylaxis

• The World Health Organization recommends administering three 1.0 mL injections intramuscularly on days 0, 7, and 21 or 28 for pre-exposure vaccination 34
• This schedule is recommended for persons at continuous or frequent risk of rabies exposure (laboratory workers, veterinarians, animal control officers, cavers, bat handlers) 34

Rabies Post-Exposure Prophylaxis Management

Efficacy of Incomplete Regimens

• Over 1,000 persons annually in the United States receive only 3 or 4 doses instead of the complete regimen, with no documented cases of rabies developing, even when >30% had confirmed exposure to rabid animals, according to the Centers for Disease Control and Prevention 35
• No case of human rabies in the United States has ever been attributed to receiving fewer than the complete vaccine course, as reported by the Centers for Disease Control and Prevention 36
• The American Academy of Pediatrics and the Centers for Disease Control and Prevention support that virus-neutralizing antibodies peak by approximately day 14-28 after starting vaccination, meaning the critical protective window occurs well before the final dose 37

Immunological Response

• The most critical period is the first 14 days when virus-neutralizing antibodies are developing—missing doses during this window matters more than missing the final dose, as stated by the World Health Organization 37
• Human rabies immune globulin (HRIG) provides immediate passive immunity at the wound site during the first 7-10 days before vaccine-induced antibodies develop, making early doses most crucial, according to the Centers for Disease Control and Prevention 35
• By day 14-28, vaccine-induced antibodies have already peaked, which explains why the later doses (particularly day 28 in older 5-dose regimens) contribute minimally to protection, as reported by the World Health Organization 37

Incubation Period and Virus Behavior

• Rabies virus has a median incubation period of ~35 days in the United States (range 5 days to >2 years), providing a substantial window for immune response development, according to the Centers for Disease Control and Prevention 37
• Once vaccine-induced antibodies appear (typically 7-10 days after starting vaccination), they can neutralize virus at the wound site and prevent CNS invasion, as stated by the World Health Organization 35

Outcome of Incomplete Vaccination

• In 192 human rabies deaths analyzed in India, all were attributable to failure to seek any PEP, and none were attributed to missing the fifth dose, as reported by the World Health Organization 36
• The Centers for Disease Control and Prevention and the World Health Organization agree that even incomplete series (3-4 doses) have prevented rabies in exposed individuals 35, 36

Rabies Vaccination Schedule Flexibility

General Guidelines

• The Advisory Committee on Immunization Practices recommends that every attempt should be made to adhere to the recommended vaccination schedules, but delays of a few days for individual doses are unimportant and do not compromise protection, according to the Centers for Disease Control and Prevention 38
• The American Committee on Immunization Practices states that taking the third dose of rabies vaccine on day 6 instead of day 7 is acceptable, as delays of a few days for individual doses are unimportant and do not compromise protection 38

Special Considerations

• If you are previously unvaccinated, human rabies immune globulin (HRIG) at 20 IU/kg must be given on day 0, and can still be administered up to and including day 7 if initially missed, as recommended by the Centers for Disease Control and Prevention 38

Rabies Post-Exposure Prophylaxis for Cat Scratch in Children

Direct Recommendation

• The Centers for Disease Control and Prevention recommends that for a child with a cat scratch that potentially exposed them to rabies, initiate full post-exposure prophylaxis (PEP) immediately if the cat is unavailable for testing, rabid, or suspected rabid, consisting of thorough wound washing, human rabies immune globulin (HRIG) at 20 IU/kg infiltrated into and around the wound, and a 4-dose rabies vaccine series (days 0, 3, 7, 14) administered intramuscularly in the deltoid or anterolateral thigh 39

Understanding Cat Scratch as Rabies Exposure

• Cat scratches contaminated with saliva or neural tissue from a potentially rabid cat constitute a nonbite exposure requiring PEP evaluation, according to the Centers for Disease Control and Prevention 40, 39, 41
• The rabies virus is transmitted when introduced into open wounds, scratches, abrasions, or mucous membranes through saliva or other infectious material, as stated by the Centers for Disease Control and Prevention 40, 39, 42
• If the material containing virus is dry, it is considered noninfectious and does not warrant prophylaxis, as noted by the Centers for Disease Control and Prevention 40, 41
• Petting a rabid animal or contact with blood, urine, or feces alone does not constitute exposure and is not an indication for prophylaxis, according to the Centers for Disease Control and Prevention 39

Risk Assessment Algorithm

• Immediate PEP is indicated if the cat is unavailable for observation or testing, as recommended by the Centers for Disease Control and Prevention 39
• In areas where rabies is enzootic in cats, or if the exposure was severe (deep scratches on face/head), the Centers for Disease Control and Prevention strongly considers initiating PEP immediately rather than waiting for observation results 43, 39

Evidence Supporting Cat Scratch as Rabies Risk

• Multiple rabies exposures requiring extensive public health investigation have occurred from cats in public settings, including pet stores and petting zoos, as reported by the Centers for Disease Control and Prevention 43

When PEP Can Be Discontinued

• If laboratory testing (direct fluorescent antibody test) confirms the cat is not rabid, PEP can be discontinued, according to the Centers for Disease Control and Prevention 39

Post-Exposure Prophylaxis in Rabies

Immediate Wound Management

• The Centers for Disease Control and Prevention recommends following wound washing with irrigation using a virucidal agent such as povidone-iodine solution if available 44

Standard PEP Regimen for Previously Unvaccinated Persons

Vaccine Administration

• The Centers for Disease Control and Prevention recommends administering 1.0 mL of human diploid cell vaccine (HDCV) or purified chick embryo cell vaccine (PCECV) intramuscularly on days 0, 3, 7, and 14 44
• The Centers for Disease Control and Prevention recommends injecting in the deltoid muscle for adults and older children; use the anterolateral thigh for young children 44

HRIG Administration

• The Centers for Disease Control and Prevention recommends administering HRIG at exactly 20 IU/kg body weight on day 0, ideally simultaneously with the first vaccine dose 44
• The Centers for Disease Control and Prevention recommends infiltrating the full calculated dose around and into the wound(s) if anatomically feasible; inject any remaining volume intramuscularly at a site distant from vaccine administration 44
• The Centers for Disease Control and Prevention recommends not administering HRIG in the same syringe or at the same anatomical site as the vaccine 44
• The Centers for Disease Control and Prevention recommends not exceeding 20 IU/kg—higher doses suppress active antibody production 44

Modified Regimens for Special Populations

Previously Vaccinated Persons

• The Centers for Disease Control and Prevention recommends administering only 2 doses of vaccine on days 0 and 3; do NOT give HRIG 44
• The Centers for Disease Control and Prevention recommends this applies to anyone who has completed a recommended pre-exposure or post-exposure vaccination series with a cell culture vaccine and has documented antibody response 44

Managing Patients with Allergies or Previous Vaccine Reactions

• The Centers for Disease Control and Prevention notes that modern cell culture vaccines (HDCV and PCECV) have uncommon adverse reactions compared to older nerve tissue-based products 44, 45
• The Centers for Disease Control and Prevention notes that no adverse events have been correlated to failure to receive the fifth vaccine dose in the older 5-dose schedule 44, 45

Common Pitfalls to Avoid

• The Centers for Disease Control and Prevention recommends not using the gluteal area for vaccine administration 44
• The Centers for Disease Control and Prevention recommends not exceeding the recommended HRIG dose of 20 IU/kg 44

Rabies Post-Exposure Prophylaxis Guidelines

Introduction to Rabies Prophylaxis

• The Centers for Disease Control and Prevention recommends that for individuals who have been exposed to rabies and have not been previously vaccinated, post-exposure prophylaxis should be initiated as soon as possible, ideally within 24 hours, with a regimen that includes wound care, human rabies immune globulin (HRIG), and a series of rabies vaccinations, with a nearly 100% effectiveness in preventing human rabies when administered promptly and appropriately 46, 47

Vaccine Administration and HRIG Protocol

• The World Health Organization and the Centers for Disease Control and Prevention suggest that HRIG should be administered at exactly 20 IU/kg body weight on day 0, ideally simultaneously with the first vaccine dose, and infiltrated around and into the wound(s) if anatomically feasible, with any remaining volume injected intramuscularly at a site distant from vaccine administration, and never exceeding 20 IU/kg as higher doses suppress active antibody production 46, 47
• The Centers for Disease Control and Prevention advises that HRIG should never be administered in the same syringe or at the same anatomical site as the vaccine, and if HRIG was not given on day 0, it can still be administered up to and including day 7 of the vaccine series, but not beyond day 7 46, 47

Special Considerations for Immunocompromised Patients

• The Centers for Disease Control and Prevention recommends that immunocompromised patients, including those with corticosteroid use, other immunosuppressive agents, antimalarials, HIV infection, chronic lymphoproliferative leukemia, or other immunosuppressive illnesses, require a 5-dose vaccine regimen on days 0, 3, 7, 14, and 28, plus HRIG at 20 IU/kg on day 0, even if previously vaccinated, and mandatory serologic testing one or more serum samples for rabies virus-neutralizing antibody by rapid fluorescent focus inhibition test (RFFIT) 1-2 weeks after the final vaccine dose 46, 47

Efficacy of Rabies Post-Exposure Prophylaxis

• The Centers for Disease Control and Prevention states that when administered promptly and appropriately, rabies post-exposure prophylaxis combining wound care, HRIG infiltration, and the vaccine series is nearly 100% effective in preventing human rabies, with no failures documented in the United States since current biologics have been licensed 47

Rabies Post-Exposure Prophylaxis Guidelines

Dosing and Administration

• The Centers for Disease Control and Prevention recommends a standard dose of 20 IU/kg body weight for rabies immune globulin, regardless of age, including children 48, 49, 50
• The dose should be administered on day 0, ideally simultaneously with the first rabies vaccine dose, and infiltrated around and into the wound(s) if anatomically feasible 49, 50

Critical Administration Guidelines

• The dose should be administered by infiltrating the full calculated dose around and into the wound(s) if anatomically feasible, with any remaining volume given intramuscularly at a site distant from vaccine administration 49, 50
• Never administer in the same syringe or at the same anatomical site as the vaccine, as this can interfere with vaccine efficacy 49, 50

Timing Considerations

• If not administered on day 0, rabies immune globulin can still be given up to and including day 7 after the first vaccine dose 49
• Beyond day 7, do not administer rabies immune globulin, as vaccine-induced antibody response is presumed to have occurred and additional passive antibody may suppress active antibody production 49, 51

Critical Dosing Pitfall to Avoid

• Do not exceed 20 IU/kg, as higher doses can partially suppress active antibody production from the vaccine, potentially compromising protection 49, 50, 51

Vaccine Co-Administration

• The child should also receive the 4-dose rabies vaccine series (1.0 mL intramuscularly on days 0, 3, 7, and 14) in the deltoid or anterolateral thigh, at a different anatomical site from the immune globulin 49, 50

Rabies Post‑Exposure Prophylaxis (PEP) Guidelines

Immediate Wound Management

• Thorough wound cleansing with soap and water for at least 15 minutes is the single most effective measure to prevent rabies infection. CDC recommends this as the first step after exposure. 52

Vaccine Administration Schedules

Previously Unvaccinated Individuals (Immunocompetent)

• Administer a four‑dose series of 1 mL rabies vaccine (human diploid cell, adsorbed, or purified chick embryo cell) intramuscularly on days 0, 3, 7, and 14, combined with a single dose of human rabies immune globulin (HRIG) 20 IU/kg on day 0. CDC guidance. 53

Previously Vaccinated Individuals (Immunocompetent)

• Provide only two vaccine doses on days 0 and 3; HRIG is not required. CDC guidance. 53

Immunocompromised Patients (Regardless of Prior Vaccination)

• Use a five‑dose vaccine schedule on days 0, 3, 7, 14, and 28, plus HRIG 20 IU/kg on day 0. CDC guidance. 53

Pre‑Exposure Prophylaxis for High‑Risk Groups

• Give three 1 mL vaccine doses intramuscularly on days 0, 7, and 21 or 28 to persons with occupational or travel risk. CDC guidance. 54

Injection Site Recommendations

• Adults and older children: Deltoid muscle. CDC guidance. 52
• Infants and young children: Anterolateral aspect of the thigh. CDC guidance. 52
• Never use the gluteal region for rabies vaccine, as it yields inadequate antibody response and vaccine failure. CDC guidance. 52

Human Rabies Immune Globulin (HRIG) Administration

• Dose: 20 IU/kg body weight, administered on day 0 (or up to day 7 if missed). CDC guidance. 52
• Technique: Infiltrate the calculated dose around and into all wounds when anatomically feasible; any remaining volume is injected intramuscularly at a site distant from the vaccine injection. CDC guidance. 52
• Never mix HRIG with vaccine in the same syringe or give them at the same anatomical site. CDC guidance. 52
• Do not exceed 20 IU/kg; higher doses suppress the active antibody response. CDC guidance. 52

Timing and Flexibility

• HRIG may be given up to day 7 after the first vaccine dose; after day 7 it should be omitted because vaccine‑induced antibodies are presumed to have developed. CDC guidance. 52
• Small delays of a few days between vaccine doses do not compromise protection; substantial delays (weeks) warrant serologic testing 7–14 days after the final dose. CDC guidance (implicit from schedule flexibility). 53

Efficacy and Outcomes

• When the recommended PEP regimen is started promptly, it is nearly 100 % effective at preventing clinical rabies. CDC data. 53
• All immunocompetent individuals completing the four‑dose schedule achieve neutralizing antibody titers ≥0.5 IU/mL by day 14, with seroprotection maintained through at least day 180. CDC data. 53
• No human rabies cases in the United States have been linked to incomplete or abbreviated rabies vaccine courses since the adoption of cell‑culture vaccines. CDC data. 53

Incubation Period

• Typical incubation is 1–3 months but can range from a few days to more than a year. CDC information. 53

Strength of evidence: The cited CDC recommendations are based on expert consensus and epidemiologic data; specific grading (e.g., Level A/B) is not provided in the source documents.

Management of Fever After the Second Rabies Vaccine Dose (CDC Guidelines)

Expected Adverse Reactions

• Mild systemic reactions such as fever, headache, dizziness, and gastrointestinal symptoms occur in 6.8 %–55.6 % of rabies vaccine recipients, and are more frequent than serious adverse events. 55
• Local injection‑site reactions (pain, redness, swelling) are reported in 60 %–89.5 % of recipients and typically resolve spontaneously within a few days. 55
• No serious adverse events have been documented in multiple pediatric studies of rabies post‑exposure prophylaxis that included both vaccine and human rabies immune globulin (HRIG). 55
• Systemic hypersensitivity reactions (urticaria, pruritic rash, angioedema) occur in approximately 5.6 % of school‑aged children (5–13 years) but usually after booster doses in previously vaccinated individuals, not during initial post‑exposure prophylaxis. 55

Symptomatic Management

• Treat fever with age‑appropriate dosing of acetaminophen (10–15 mg/kg every 4–6 h) or ibuprofen (5–10 mg/kg every 6–8 h). 55
• Provide adequate hydration and rest while the child experiences mild systemic symptoms. 55

Monitoring for Serious Reactions

• Immediate hypersensitivity reactions (anaphylaxis) are extremely rare (~1 in 10,000 vaccinees) and most often occur after the first dose, not subsequent doses. 55
• If any urticaria, angioedema, respiratory difficulty, or other signs of anaphylaxis develop, seek urgent medical care. 55
• Simple fever without accompanying rash, respiratory compromise, or hemodynamic instability does not require interruption of the vaccine series. 55

Clinical Decision‑Making

• Do not discontinue the rabies vaccine series for mild systemic reactions such as fever; continuation is essential for protection against a uniformly fatal disease. 55
• Fever persisting beyond 48–72 hours after vaccination may suggest an unrelated infection and should prompt evaluation. 55
• Neurologic symptoms (e.g., seizures, altered mental status) are extremely rare after modern cell‑culture rabies vaccines, and no causal link has been established; such symptoms warrant immediate assessment. 55

Parent Counseling

• Fever after vaccination indicates an appropriate immune response to the rabies antigen. 55
• Mild systemic reactions do not predict vaccine failure nor increase the risk of serious adverse events. 55

Rabies Post‑Exposure Prophylaxis Guidelines for Monkey Bites

Immediate Wound Management

• Thorough wound cleansing – Wash the bite wound with soap and water for at least 15 minutes immediately after exposure; animal‑model studies show this is the most effective single measure for reducing viral load. (CDC) 56
• Tetanus assessment – Evaluate the patient’s tetanus immunization status and provide tetanus prophylaxis when indicated. (CDC) 56

Human Rabies Immune Globulin (HRIG)

• Standard HRIG dose – Administer HRIG at 20 IU per kilogram of body weight on day 0, preferably at the same time as the first rabies vaccine dose. (CDC) 56
• Wound infiltration – Infiltrate the entire calculated HRIG dose around and into each bite wound whenever anatomically feasible; any remaining volume should be given intramuscularly at a site distant from the vaccine injection. (CDC) 56
• Timing window – HRIG may be given up to and including day 7 after exposure if not administered earlier, but must not be given after day 7 because vaccine‑induced antibodies are presumed to be present by then. (CDC) 56
• Maximum dose limit – Do not exceed 20 IU/kg; higher doses have been shown to suppress the active antibody response generated by the vaccine. (CDC) 56

Rabies Vaccine Series

• Four‑dose schedule – Provide four intramuscular doses of a cell‑culture rabies vaccine (HDCV or PCECV), 1.0 mL each, on days 0, 3, 7, and 14. (CDC) 56
• Injection site recommendations – Administer the vaccine in the deltoid muscle for adults and older children and in the anterolateral thigh for young children to ensure optimal immunogenicity. (CDC) 56

Efficacy and Safety

• Near‑100 % effectiveness – When the complete regimen (HRIG plus vaccine series) is initiated promptly and followed correctly, it is virtually 100 % effective at preventing clinical rabies. (CDC) 56
• No documented prophylaxis failures – Since the licensing of modern cell‑culture rabies vaccines and HRIG in the United States, no failures of post‑exposure prophylaxis have been reported when the protocol is adhered to. (CDC) 56

Rabies Exposure – Immediate Wound Management Recommendations

Tetanus Prophylaxis and Antibiotic Use

• The CDC recommends that patients with potential rabies exposure receive tetanus prophylaxis and appropriate antibiotics to prevent secondary bacterial infection of the wound. 57

Suturing Considerations

• The CDC advises avoiding suturing of large rabies‑exposed wounds whenever possible, unless closure is required for cosmetic reasons or there is a high risk of bacterial infection. 57

Rabies Post‑Exposure Prophylaxis Recommendations for Previously Vaccinated and Immunocompromised Individuals

Previously Vaccinated Immunocompetent Patients

• The CDC recommends a simplified PEP regimen of two 1.0 mL doses of cell‑culture rabies vaccine administered on days 0 and 3. 58, 59
• The CDC advises that human rabies immune globulin (HRIG) should not be given to previously vaccinated persons because it can inhibit the anamnestic antibody response. 58, 59
• The CDC defines “previously vaccinated” as having completed an ACIP‑recommended pre‑ or post‑exposure prophylaxis schedule with cell‑culture vaccines, or an alternative regimen with documented adequate rabies virus‑neutralizing antibody titers. 58, 59

Immunocompromised Patients (All Prior Vaccination Statuses)

• The CDC recommends an extended rabies vaccine schedule of five 1.0 mL doses given on days 0, 3, 7, 14, and 28 for immunocompromised individuals. 60, 58, 59
• The CDC notes that immunosuppressive conditions (e.g., corticosteroids, other immunosuppressive agents, antimalarials, HIV infection, or immunosuppressive illnesses) markedly diminish immune responses to rabies vaccines. 60, 58, 59
• The CDC requires mandatory serologic testing for rabies virus‑neutralizing antibodies (RFFIT) 1–2 weeks after the final vaccine dose, with a target titer of ≥ 1:5, to confirm an adequate immune response. 60, 58, 59
• If the post‑vaccination antibody titer is insufficient, the CDC advises management in consultation with the patient’s physician and public health officials. 60, 58, 59

HRIG Administration Considerations

• The CDC cautions that HRIG must never be administered to previously vaccinated immunocompetent patients, as it suppresses the memory immune response. 58, 59

Timing and Administration of Human Rabies Immune Globulin (HRIG) in Post‑Exposure Prophylaxis

1. Timing Window for HRIG

• HRIG may be administered up to and including day 7 after the first rabies vaccine dose if it was omitted initially; this does not compromise protective immunity. 61
• The ideal time for HRIG is day 0 (the same day as the first vaccine dose), using a dose of 20 IU/kg body weight; the calculated volume should be infiltrated around and into all wounds when feasible, with any remaining volume injected intramuscularly at a site distant from the vaccine injection. 61
• Beyond day 7, HRIG should not be given because an active antibody response to the cell‑culture vaccine is presumed to have occurred, and additional passive antibody may partially suppress the vaccine‑induced response. 61

2. Rationale for the Day‑7 Cutoff

• The active immune response to rabies vaccine requires approximately 7–10 days to develop; HRIG supplies immediate passive, virus‑neutralizing antibodies to bridge this gap. 62

3. Critical Administration Guidelines for Delayed HRIG

• Never mix HRIG with the vaccine in the same syringe or inject it at the same anatomical site; doing so can interfere with vaccine efficacy. 61
• Do not exceed the recommended dose of 20 IU/kg; higher doses have been shown to partially suppress the active antibody response to the vaccine. 61
• Infiltrate the full calculated dose around and into all wounds (when anatomically feasible) because local wound infiltration is essential for neutralizing virus at the exposure site. 61

4. Clinical Decision‑Making

• When a patient presents within the 7‑day window, HRIG should be given immediately; if the presentation is after day 7, HRIG is omitted and the vaccine series continues alone. 61

5. Exception – Previously Vaccinated Persons

• Individuals with prior rabies vaccination should receive only two vaccine doses (days 0 and 3) and should never receive HRIG, even if it was missed initially, because HRIG can inhibit the anamnestic (memory) antibody response. 61

ACIP Recommendations for a 4‑Dose Rabies Post‑Exposure Prophylaxis Schedule

Rationale for Reducing the Schedule

• The Advisory Committee on Immunization Practices (ACIP) shortened the rabies post‑exposure prophylaxis (PEP) regimen from five to four vaccine doses in 2010 because extensive evidence demonstrated that four doses combined with rabies immune globulin (RIG) generate adequate protective antibody levels, and the fifth dose on day 28 does not improve clinical outcomes【63】【64】.

Safety and Efficacy Evidence

Real‑World Safety Data (United States)

• Annually, >1,000 individuals in the United States who received only three or four rabies vaccine doses (instead of the full five) experienced no documented cases of human rabies, even though more than 30 % had confirmed exposure to rabid animals【63】.
• Nationwide surveillance has found no human rabies cases attributable to receiving fewer than five doses when modern cell‑culture rabies vaccines are used【63】.

Global PEP Failure Analysis

• A review of 21 documented rabies PEP failures in Burma, India, the Philippines, South Africa, Sri Lanka, and Thailand (1984‑2007) showed that 20 patients developed symptoms and 15 died before day 28, and none of these failures were linked to omission of the day‑28 (fifth) dose【63】.

Current 4‑Dose Regimen for Previously Unvaccinated Persons

Vaccine Administration Schedule

• Administer 1.0 mL of human diploid cell vaccine (HDCV) or purified chick embryo cell vaccine (PCECV) intramuscularly on days 0, 3, 7, and 14【63】【64】.
• On day 0, give human rabies immune globulin (HRIG) at 20 IU/kg body weight, infiltrating the wound(s) as anatomically feasible【63】【64】.
• Use the deltoid muscle for adults and older children; use the anterolateral thigh for young children, and avoid gluteal injection sites【63】【64】.

Safety Profile

• Modern cell‑culture rabies vaccines are associated with uncommon adverse reactions compared with older nerve‑tissue vaccines【63】 (observational safety data).
• The ACIP Rabies Working Group found no adverse events linked to omission of the fifth dose, supporting the safety of the 4‑dose schedule【63】.
• Skipping the day‑28 dose may confer additional health benefits by reducing the cumulative risk of vaccine‑related adverse events, since each injection carries an independent risk【63】.

Economic Impact

• Reducing the regimen from five to four doses is estimated to save approximately $16.6 million annually in the U.S. health‑care system, assuming full compliance with the recommended schedule【63】.
• Patients also benefit from lower vaccine costs and the elimination of an extra clinic visit required for the fifth dose【63】.